North Caldwell, NJ, United States of America

Manfred Weigele

This inventor holds 31 USPTO granted patents. Top assignees: Hoffmann-La Roche Inc., The United States of America. Active years: 1976-1994.


% Patents Active = 100.0

Average Co-Inventor Count = 2.6

ph-index = 8

Forward Citations = 194(Granted Patents)


Location History:

  • Clifton, NJ (US) (1992)
  • North Caldwell, NJ (US) (1976 - 1994)

Company Filing History:


Years Active: 1976-1994

Loading Chart...
Areas of Expertise:
Antibacterial Cephalosporin Compounds
Anti-Retroviral Compounds
Beta-Lactamase Inhibitors
Fluorogenic Materials
Diagnostic Test
Imidazole Derivatives
Penicillanic Acid Derivatives
Oxazinomycin Production
Spirolactone Production
Dideoxynucleosides
Amino Acid Derivatives
Pyrazomycin Preparation
31 patents (USPTO):Explore Patents

Title: Inventor Manfred Weigele

Introduction: Manfred Weigele is a renowned inventor based in North Caldwell, NJ (US) known for his groundbreaking contributions to various industries.

Latest Patents: Manfred Weigele holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovations.

Career Highlights: Throughout his career, Manfred Weigele has demonstrated a keen ability to identify gaps in the market and develop inventive solutions to address them. His innovative mindset has led to the creation of products that have significantly impacted their respective industries.

Collaborations: Manfred Weigele has collaborated with leading companies, research institutions, and universities to further develop and commercialize his inventions. These partnerships have been instrumental in bringing his ideas to life and making a tangible difference in the world.

Conclusion: Manfred Weigele's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor. His contributions continue to inspire the next generation of inventors to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…